Silence Therapeutics PLC (nasdaq:SLN) Share Price

Company Profile

Business description
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Contact
12 Hammersmith Grove
LondonW6 7AP
GBR
T: +44 2034576900
E: [email protected]
https://www.silence-therapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
88

Recommended

Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.

Morningstar | 28 September 2026

Trading at an 18% discount, this wide-moat stock is a rare find.

Malik Ahmed Khan, CFA | 22 September 2026

Discounted exit raises investor concerns.

Yingqi Tan, CFA | 21 September 2026

Index	Last price	Change	% Change
All Ordinaries	8,886.60	35.90	0.41%
CAC 40	8,091.95	13.47	0.17%
DAX 40	25,515.38	140.96	0.56%
Dow JONES (US)	51,481.51	347.11	-0.67%
FTSE 100	10,724.83	39.95	0.37%
HKSE	24,523.57	118.94	-0.48%
NASDAQ	26,820.38	248.34	-0.92%
Nikkei 225	65,481.27	396.35	-0.60%
NZX 50 Index	13,683.63	147.05	-1.06%
S&P 500	7,683.69	59.72	-0.77%
S&P/ASX 200	8,709.30	29.60	0.34%
SSE Composite Index	3,830.45	6.83	0.18%